LeMaitre VascularvsMerck & Company

LMAT and MRK stock compared: price, dividend, valuation and results, from SEC filings.

LMAT

LeMaitre Vascular, Inc.

$75.58

Value $1.7B

-0.68%
LMAT's page

MRK

Merck & Company, Inc.

$137.78

Value $341B

-3.90%
MRK's page

LeMaitre Vascular (LMAT) has a market value of $1.7B and Merck & Company (MRK) $341B. Over the last year, with dividends, LMAT moved -12.2% and MRK +52.7%. The P/E is 27.2 for LMAT and 138.9 for MRK. Dividend yield: LMAT 1.26%, MRK 2.47%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    LMAT$1.7B

    MRK$341B

    MRK is 198 times LMAT

  • Revenue, 12 months

    LMAT$269M

    MRK$67.4B

    MRK is 250 times LMAT

  • Net income, 12 months

    LMAT$63M

    MRK$2.5B

    MRK is 39 times LMAT

  • Operating margin

    LMAT27.7%

    MRK–

  • ROIC

    LMAT10.1%

    MRK3.9%

    6.2 points apart

  • P/E

    LMAT27.2

    MRK138.9

    MRK is 5.1 times LMAT

  • Dividend yield

    LMAT1.3%

    MRK2.5%

    1.2 points apart

  • 5-year return

    LMAT+48.2%

    MRK+94.3%

    46.1 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

LMAT+48.2%

MRK+94.3%

10015020020222023202420252026
Returns by period
PeriodLMATWith dividendsMRKWith dividends
1 year since November 17, 2025-12.2%Price -13.1%+52.7%Price +48.4%
3 years since November 17, 2023+45.9%+13.4% a yearPrice +42.3%+48.4%+14.1% a yearPrice +35.4%
5 years since November 17, 2021+48.2%+8.2% a yearPrice +41.2%+94.3%+14.2% a yearPrice +66.8%
10 years since November 21, 2016+240.1%+13.0% a yearPrice +209.5%+214.5%+12.1% a yearPrice +131.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

LMATLeMaitre VascularMRKMerck & Company

Valuation

LMATMRK
Valuation
Price$75.58$137.78
Market value$1.7B$341B
Enterprise value (EV)$1.5B$385B
P/E27.2138.9
P/E, 5-year median42.414.8
P/B4.07.6
EV/EBIT20.180.8
Free cash flow yield3.9%4.3%

Results and growth

LMATMRK
Results and growth
Revenue, 12 months$269M$67.4B
Net income, 12 months$63M$2.5B
Free cash flow, 12 months$67M$14.7B
Earnings per share, 12 months$2.75$0.98
Revenue growth, year on year13.5%1.3%
Revenue growth a year, past+14.1%over 5 years+9.4%over 5 years
EPS growth a year, past+19.4%over 5 years+21.2%over 5 years

Margins and returns on capital

LMATMRK
Margins and returns on capital
Gross margin72.0%71.8%
Operating margin27.7%–
Net margin23.5%3.6%
ROIC10.1%3.9%
ROE15.6%5.2%

Balance sheet

LMATMRK
Balance sheet
Cash$390M$9.7B
Total debt$189M$53.8B
Net debt / EBITDA-2.65.7
Interest cover14.4×2.4×

Dividends and buybacks

LMATMRK
Dividends and buybacks
Dividend yield1.3%2.5%
Dividend per share, 12 months$0.95$3.40
Dividend growth a year, past+16.1%over 5 years+5.8%over 5 years
Buyback yield0.1%1.5%
Shareholder yield1.4%4.0%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: LMAT or MRK

Didn't find what you were looking for?

Ask us
Which is bigger, LeMaitre Vascular or Merck & Company?

By market value, Merck & Company ($341B) is about 197.9 times LeMaitre Vascular ($1.7B), at today's prices.

How did LMAT and MRK stock do over the last 10 years?

Since November 21, 2016, LMAT's price moved +209.5% and MRK's +131.8%. With dividends: LMAT +240.1% (+13.0% a year), MRK +214.5% (+12.1% a year). Past returns do not predict future ones.

Which pays the higher dividend, LMAT or MRK?

The dividend yield at today's price is 1.26% for LeMaitre Vascular and 2.47% for Merck & Company. Over the last twelve months they paid $0.95 and $3.40 per share.

What is the P/E of LMAT and MRK?

At today's price, the P/E is 27.2 for LMAT and 138.9 for MRK. The median of the last five years was 42.4 and 14.8, which shows where each stands against its own past.

Which has the higher profit margins, LeMaitre Vascular or Merck & Company?

Over the last twelve months, the net margin was 23.5% for LeMaitre Vascular and 3.6% for Merck & Company, and the operating margin 27.7% and –. Revenue was $269M and $67.4B.

Which is the better investment, LeMaitre Vascular or Merck & Company?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.